Here’s a closer look at TIGIT and its potential in #cancer therapy. This target is primed to gain more traction in immuno-oncology this year. (Thread below)

Key players developing anti-TIGIT therapies are $RHHBY $MRK $BMY $RCUS $ALPMY $BGNE $CGEN $SGEN $MREO $IVBXF & @iTeosTx TIGIT is an inhibitory receptor expressed by activated T-cells, T-regs & NK cells

- Ligand for TIGIT (PVR) is expressed in multiple tumor types
- Activation suppresses T-cell activity
- Upregulated during PD-1 blockade

@Cancer_Cell paper (open access): cell.com/cancer-cell/fu…

Good review of natural killer (NK) cells for #cancer immunotherapy from @NatRevDrugDisc: nature.com/articles/s4157…

#CellTherapy $TAK $FATE $NK @CellMedica & Century Therapeutics @NatRevDrugDisc @CellMedica A Ph 1/2 study from @MDAndersonNews showed promising clinical data of HLA-mismatched anti-CD19 CAR-NK #CellTherapy in NHL/CLL #cancer patients (n=11): 73% ORR & 64% CR(!)

@NEJM paper: nejm.org/doi/full/10.10…

$TAK has licensed this product. Competitively relevant to $FATE.

Excellent overview of the cell therapy landscape from Piper Jaffray

$GILD $NVS $CELG $JNJ $AMGN $ALLO $BLUE $IOVA $AUTL $SGMO $ATRA $CRSP $FATE $CLLS $NTLA $DTIL $ZIOP $MRKR $CYAD $BLCM $TCRR $ADAP $MBIO $NTGN $UMRX $MXCT $GMDA $SRNE $KDS $MDGEF $NK $ANIX $KITE $JUNO #ASGCT19 New article from @NatRevDrugDisc looks at the global #CellTherapy landscape: nature.com/articles/d4157…

Now, the global cell therapy pipeline includes 1,011 active agents, 258 more than a year ago.

#ASCO19